{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:18:09Z","timestamp":1791235089743,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024A1515013289"],"award-info":[{"award-number":["2024A1515013289"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2023B03J1243"],"award-info":[{"award-number":["2023B03J1243"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,370,383"],"award-info":[{"award-number":["82,370,383"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ejim.2025.02.013","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T14:53:27Z","timestamp":1739112807000},"page":"140-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Factor XI\/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation"],"prefix":"10.1016","volume":"137","author":[{"given":"Shan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wulamiding","family":"Kaisaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1280-0158","authenticated-orcid":false,"given":"Wengen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejim.2025.02.013_bib0001","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4103\/hm.HM-D-23-00075","article-title":"Cognitive function in atrial fibrillation: a narrative review of evidence and mechanisms","volume":"8","author":"Agarwal","year":"2024","journal-title":"Heart Mind"},{"issue":"10","key":"10.1016\/j.ejim.2025.02.013_bib0002","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2025.02.013_bib0003","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1016\/j.ejim.2025.02.013_bib0004","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New Engl J Med"},{"issue":"22","key":"10.1016\/j.ejim.2025.02.013_bib0005","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ejim.2025.02.013_bib0006","article-title":"Reappraisal of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a systematic review and meta-analysis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ejim.2025.02.013_bib0007","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2023.08.001","article-title":"A new strategy for anticoagulation: the factor XI inhibitors","volume":"116","author":"Vedovati","year":"2023","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.02.013_bib0008","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"AZALEA\u2013TIMI 71 investigators. Abelacimab versus Rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.02.013_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"OCEANIC-AF steering committee and investigators. Asundexian versus Apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"issue":"10333","key":"10.1016\/j.ejim.2025.02.013_bib0010","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"PACIFIC-AF investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620525000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T17:30:04Z","timestamp":1753723804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620525000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":10,"alternative-id":["S0953620525000548"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.02.013","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI\/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}